(Q46205664)

20 December 2017

title

Prise en charge of metastatic renal carcinoma (English)

1 reference

20 December 2017

author name string

A Méjean

series ordinal

1

1 reference

20 December 2017

T Lebret

series ordinal

2

1 reference

20 December 2017

language of work or name

French

0 references

publication date

1 November 2008

1 reference

20 December 2017

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

published in

1 reference

20 December 2017

volume

18 Suppl 7

1 reference

20 December 2017

page(s)

S298-308

1 reference

20 December 2017

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Preoperative nomogram predicting 12-year probability of metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

The changing evolution of renal tumours: a single center experience over a two-decade period

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Differences in organ system of distant metastasis by renal cell carcinoma subtype

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

1 reference

7 January 2021

Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Resection of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Long-term results after pulmonary resection of renal cell carcinoma metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Pulmonary resection of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Simultaneous thoracoscopic wedge resection of a solitary lung nodule and laparoscopic partial nephrectomy for a renal mass.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Late pulmonary metastasis of renal cell carcinoma resected 25 years after nephrectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Pulmonary arteriovenous fistula arising in a renal cell carcinoma lung metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Pulmonary arteriovenous fistula in a patient with renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Treatment of osseous metastases in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Spinal metastasis from renal cell carcinoma, 31 years following nephrectomy--case report

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Integrating metastasectomy in the management of advanced urological malignancies-where are we in 2005?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Surgery for solitary metastases of the spine: rationale and results of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Hepatic resection for metastatic renal tumors: is it worthwhile?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Rupture of a hepatic metastasis from renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Surgical resection of metastatic intraventricular tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Gamma knife radiosurgery for brainstem metastases: the UCSF experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Cytotoxic chemotherapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Ras regulation of vascular endothelial growth factor and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

The Ras-Raf-MEK-ERK pathway in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Bcl-2 targets the protein kinase Raf-1 to mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2808%2974558-5

7 January 2021

10.1016/S1166-7087(08)74558-5

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017